• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cardiovascular Benefit With SGLT2 Inhibition


John B. Buse, MD, PhD: One of the most interesting questions about the SGLT2 inhibitors is, how is it that cardiovascular risk is reduced by these agents? There are the straightforward, potential answers like, “It lowers glucose.” Because it’s associated with loss of glucose in the urine, losing calories, it is associated with weight loss. It’s also associated with a reduction in blood pressure. But the benefit seems to be greater than would be expected by those sorts of modest effects on classic cardiovascular risk factors.

It has been suggested that a number of mechanisms might be operative, one being that these drugs increase the amount of ketone bodies that circulate. These ketone bodies are important fuels, particularly for the heart, the brain, and the kidney. And there is a greater efficiency when tissues use ketone bodies as a fuel, as opposed to using glucose or fatty acids. That efficiency might really translate into particular benefits in the ischemic heart, the injured brain, or the failing kidney. So, that’s an idea that’s out there now. I’m not sure that’s the answer, because the increase in ketone bodies is really pretty modest, but it’s certainly one of the possibilities.

The other is that perhaps it’s more of an osmotic effect, a diuretic effect. I think there is some evidence that that’s not really the mechanism. Some suggest that it might be an anti-inflammatory effect. I think we really don’t know what the mechanism is. The benefit is really shockingly large, and it is of great interest to figure out how this large benefit occurs, because perhaps we can target those pathways more directly.

Related Videos
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"
Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"
Video 12 - "The Future of Ph+ ALL Treatments"
dr lawrence eichenfield
dr krystyn van vliet
Raajit Rampal, MD, PhD, screenshot
Related Content
© 2024 MJH Life Sciences
All rights reserved.